Zhejiang Xianju Pharmaceutical Co.,Ltd.

SZSE:002332 Lagerbericht

Marktkapitalisierung: CN¥12.5b

Zhejiang Xianju PharmaceuticalLtd Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Zhejiang Xianju PharmaceuticalLtd is forecast to grow earnings and revenue by 22% and 16.6% per annum respectively. EPS is expected to grow by 21.9% per annum. Return on equity is forecast to be 13.6% in 3 years.

Wichtige Informationen

22.0%

Wachstumsrate der Gewinne

21.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum19.3%
Wachstumsrate der Einnahmen16.6%
Zukünftige Eigenkapitalrendite13.6%
Analystenabdeckung

Good

Zuletzt aktualisiert27 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Zhejiang Xianju PharmaceuticalLtd (SZSE:002332) Seems To Use Debt Quite Sensibly

Oct 16
Zhejiang Xianju PharmaceuticalLtd (SZSE:002332) Seems To Use Debt Quite Sensibly

A Look At The Intrinsic Value Of Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332)

Sep 03
A Look At The Intrinsic Value Of Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332)

Zhejiang Xianju PharmaceuticalLtd (SZSE:002332) Will Pay A Dividend Of CN¥0.30

Jun 02
Zhejiang Xianju PharmaceuticalLtd (SZSE:002332) Will Pay A Dividend Of CN¥0.30

Estimating The Fair Value Of Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332)

Apr 15
Estimating The Fair Value Of Zhejiang Xianju Pharmaceutical Co.,Ltd. (SZSE:002332)

There Is A Reason Zhejiang Xianju Pharmaceutical Co.,Ltd.'s (SZSE:002332) Price Is Undemanding

Mar 05
There Is A Reason Zhejiang Xianju Pharmaceutical Co.,Ltd.'s (SZSE:002332) Price Is Undemanding

Gewinn- und Umsatzwachstumsprognosen

SZSE:002332 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20266,0951,026N/A1,1188
12/31/20255,263842N/A8988
12/31/20244,563686N/A8008
9/30/20244,12362272324N/A
6/30/20244,143601227448N/A
3/31/20244,204581385635N/A
12/31/20234,123563361595N/A
9/30/20234,164692493732N/A
6/30/20234,270720444723N/A
3/31/20234,288755414673N/A
1/1/20234,380749327609N/A
9/30/20224,493689239535N/A
6/30/20224,442676277552N/A
3/31/20224,405636318599N/A
1/1/20224,357619409658N/A
9/30/20214,402605667807N/A
6/30/20214,391573644779N/A
3/31/20214,276548655759N/A
12/31/20204,019505671789N/A
9/30/20203,873478452589N/A
6/30/20203,620442165415N/A
3/31/20203,618420234512N/A
12/31/20193,709410257520N/A
9/30/20193,741381162358N/A
6/30/20193,723352313455N/A
3/31/20193,628319275422N/A
12/31/20183,62230124193N/A
9/30/20183,51427774316N/A
6/30/20183,337249N/A204N/A
3/31/20183,116231N/A116N/A
12/31/20172,853207N/A179N/A
9/30/20172,671187N/A205N/A
6/30/20172,572168N/A125N/A
3/31/20172,547149N/A133N/A
12/31/20162,504146N/A156N/A
9/30/20162,457135N/A214N/A
6/30/20162,504123N/A243N/A
3/31/20162,441108N/A257N/A
12/31/20152,480107N/A200N/A
9/30/20152,46688N/A257N/A
6/30/20152,46171N/A269N/A
3/31/20152,47360N/A118N/A
12/31/20142,47157N/A142N/A
9/30/20142,40845N/A3N/A
6/30/20142,37038N/A62N/A
3/31/20142,37351N/A59N/A
12/31/20132,31561N/A63N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 002332's forecast earnings growth (22% per year) is above the savings rate (2.9%).

Ertrag vs. Markt: 002332's earnings (22% per year) are forecast to grow slower than the CN market (25.8% per year).

Hohe Wachstumserträge: 002332's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: 002332's revenue (16.6% per year) is forecast to grow faster than the CN market (14% per year).

Hohe Wachstumseinnahmen: 002332's revenue (16.6% per year) is forecast to grow slower than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 002332's Return on Equity is forecast to be low in 3 years time (13.6%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y